Hepatitis C
Conditions
Interventions
DAAs salvage therapy group:none
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: This study included patients from the Department of Infectious Diseases, Xiangya Hospital, Central South University, between January 1, 2020 and June 30, 2028. Eligible patients were aged =20 years and were diagnosed with chronic hepatitis C virus (HCV) infection, defined by positive anti-HCV antibodies and quantifiable serum HCV RNA levels persisting for =6 months. Patients with compensated cirrhosis were also included. All enrolled patients had previously experienced treatment failure following combination therapy with direct-acting antivirals (DAAs).
Exclusion criteria
Exclusion criteria: Patients were excluded if clinical data were incomplete or if they were considered unsuitable for inclusion by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SVR12;HCV RNA;Genotype; | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT;AST;Albumin;PLT; | — |
Countries
China
Contacts
Public ContactZebing Huang
Xiangya Hospital, Central South University
Outcome results
None listed